Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to
busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving
disease eradication in patients with lymphoid malignancies not eligible for standard
transplantation.